SEE US AT
WORLD’S CLINICAL LABORATORY NEWS LEADER
MEDICA®
2022 Hall 1• H61
ISSN 1068-1760
I
N
Vol. 39 No.7 • 11/2022
T
E
Kit Detects Immunity to COVID-19 and Variants
A
s the COVID-19 pandemic continues, countries around the world are switching toward vaccinations and boosters to combat the pandemic. However, waning immunity against SARS-CoV-2 wild-type (WT) and variants have been widely reported. Booster
R
T
N
A
T
I
O
DAILY CLINICAL LAB NEWS
®
N
Study Urges Setting Up Reserve Lab Capacity for Future Pandemics
he lack of early COVID-19 PCR testing capacity had a knock-on effect on other health services in 2020. This included delaying the ability to make sure hospitals were COVID-secure and patients had surgery as safely as possible, and slowing down
the identification of people with COVID-19 in the community – which delayed contact tracing. The risk of another pandemic like COVID-19 happening is ever-present: there have been outbreaks of infectious disease throughout history. But nobody can say for
Cont’d on page 26
Cont’d on page 21
MCED Tests Mark New Era in Early Cancer Detection
I
S
I
T
LINKXPRESS COM
R E A D E R
S E R V I C E
®
P O R T A L
Renew/Start your Free Subscription Access Interactive Digital Magazine Instant Online Product Information: Identify LinkXpress codes of 1 interest as you read magazine ®
on LinkXpress.com 2 toClick reach reader service portal Mark code(s) of interest on 3 LinkXpress inquiry matrix ®
If your subscription is not renewed every 12 months your Free Subscription may be automatically discontinued
L
First Test to Diagnose Acute Rheumatic Fever
A
new project will look to identify and validate biomarkers for acute rheumatic fever (ARF), which initiates a slow but progressive process of heart valve damage dubbed rheumatic heart disease (RHD). These biomarkers will serve as a basis for the world’s first sensitive and specific diagnostic test for ARF. The collaborative network led by the Cincinnati Children’s
Rapid POC Test for Methicillin Resistance
M
Image: 3-D depiction of cancer cell and lymphocytes
See article on page 9
V
A
Cont’d on page 14
E
merging multicancer early detection (MCED) blood tests can detect a common cancer signal from over 50 different types of cancer and predict the origin of the signal in the body.
V I S I T
Blood Volume Test Cuts by Half Hospital Stay for Heart Patients
E
ffective management of patients hospitalized for heart failure remains problematic despite advances in medical therapy. Hospitals and clinicians struggle with readmissions, mortality and wasted resources. There is a need for accurate, actionable data to allow clinicians to optimize treatCont’d on page 8
Liquid Biopsy Testing Platform Offers Unprecedented Sensitivity in MRD Detection
C
urrent liquid biopsy assays are able to detect circulating tumor DNA (ctDNA) levels when tumor burden is high, but are not sensitive enough to detect minimal residual disease (MRD) when ctDNA levels are low. A significant portion of lymphoma patients even-
tually experience disease progression, and existing ctDNA assays fail to detect MRD in the majority of patients who will later relapse. Now, a novel liquid biopsy testing platform allows detection of MRD with up to a 100-fold improvement in sensitivity over existing assays. Cont’d on page 17
ethicillin-resistant (MRSA) is a major multi-resistant nosocomial pathogen worldwide with the WHO estimating that the mortality rate of patient infection rates is around 50% higher compared with patients who have been infected by non-resistant Staphylococcus aureus strains. Moreover, the extensive period of hospitalization, morbidity, and the associated medical costs inCont’d on page 18
INSIDE
COVID-19 Update. . . . . 4 Clinical News. . . . . . . . . 8 IFCC News. . . . . . . . . . 29 Product News . . . . . 6-24 Industry News . . . . . . . 33 Events Calendar . . . . . 34 PUBLISHED IN COOPERATION WITH
International Federation of Clinical Chemistry and Laboratory Medicine
GLOBETECH >>> MEDIA <<<